Company news
UroGen Pharma Ltd. news in 2022
UroGen Pharma Ltd.'s news releases, calls and decks from 2022, newest first.
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
December 18, 2022
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer
December 1, 2022
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer
November 30, 2022
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference
November 20, 2022
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma
November 13, 2022
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
November 9, 2022
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors
November 8, 2022
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022
November 2, 2022
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers
October 10, 2022
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma’s JELMYTO® Admixture to 96 Hours Following Reconstitution
September 27, 2022
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors
September 11, 2022
UroGen Pharma Announces Upcoming 2022 Conferences
September 6, 2022
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
August 10, 2022
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022
July 26, 2022
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer
May 15, 2022
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
May 12, 2022
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 9, 2022
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
May 2, 2022
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
March 28, 2022
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
March 20, 2022
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
March 7, 2022
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022
March 3, 2022
UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
February 28, 2022
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
February 27, 2022
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
February 9, 2022
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
February 2, 2022
UroGen Pharma to Present at Upcoming Conferences
January 4, 2022